“We are in a period of great momentum and execution at Structure Therapeutics ... into the differentiated profile of GSBR-1290 as a potential best-in-class oral small molecule GLP-1 receptor (GLP1-R) ...

Structure is developing an oral small molecule GLP-1 with once daily dosing. We think the GLP-1 class of obesity/diabetes ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

Jakarta, - Unlocking the Potential of Peptides in Muscle Cell and Bone Science Peptides, tiny chains of amino acids linked by ...

Piper Sandler 36 th Annual Healthcare Conference in New York on Thursday, December 5, 2024, at 8:30 a.m. ET ... leverages its ...

Q3 2024 Earnings Conference Call November 7, 2024 9:00 AM ETCompany ParticipantsPeter Cannito - Chairman, Chief ...

In animal and human cells, Hsp70 class chaperones are at the heart of this control system, overseeing a wide range of ...

About ORLADEYO ® (berotralstat) ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

CG001419 is a first-in-class, selective, clinically active ... The Company applies its proprietary uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) platform to expand the drug ...